Di-(2-ethylhexyl)-phthalate (DEHP) causes impaired adipocyte function and alters serum metabolites

Nora Klöting, Nico Hesselbarth, Martin Gericke, Anne Kunath, Ronald Biemann, Rima Chakaroun, Joanna Kosacka, Peter Kovacs, Matthias Kern, Michael Stumvoll, Bernd Fischer, Ulrike Rolle-Kampczyk, Ralph Feltens, Wolfgang Otto, Dirk K. Wissenbach, Martin Von Bergen, Matthias Blüher

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

60 Citationer (Scopus)

Abstract

Di-(2-ethylhexyl)-phthalate (DEHP), an ubiquitous environmental contaminant, has been shown to cause adverse effects on glucose homeostasis and insulin sensitivity in epidemiological studies, but the underlying mechanisms are still unknown. We therefore tested the hypothesis that chronic DEHP exposure causes impaired insulin sensitivity, affects body weight, adipose tissue (AT) function and circulating metabolic parameters of obesity resistant 129S6 mice in vivo. An obesity-resistant mouse model was chosen to reduce a potential obesity bias of DEHP effects on metabolic parameters and AT function. The metabolic effects of 10-weeks exposure to DEHP were tested by insulin tolerance tests and quantitative assessment of 183 metabolites in mice. Furthermore, 3T3-L1 cells were cultured with DEHP for two days, differentiated into mature adipocytes in which the effects on insulin stimulated glucose and palmitate uptake, lipid content as well as on mRNA/protein expression of key adipocyte genes were investigated. We observed in female mice that DEHP treatment causes enhanced weight gain, fat mass, impaired insulin tolerance, changes in circulating adiponectin and adipose tissue Pparg, adiponectin and estrogen expression. Serum metabolomics indicated a general increase in phospholipid and carnitine concentrations. In vitro, DEHP treatment increases the proliferation rate and alters glucose uptake in adipocytes. Taken together, DEHP has significant effects on adipose tissue (AT) function and alters specific serum metabolites. Although, DEHP treatment led to significantly impaired insulin tolerance, it did not affect glucose tolerance, HOMA-IR, fasting glucose, insulin or triglyceride serum concentrations. This may suggest that DEHP treatment does not cause impaired glucose metabolism at the whole body level.

OriginalsprogEngelsk
Artikelnummere0143190
TidsskriftPLoS ONE
Vol/bind10
Udgave nummer12
ISSN1932-6203
DOI
StatusUdgivet - 1 dec. 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Di-(2-ethylhexyl)-phthalate (DEHP) causes impaired adipocyte function and alters serum metabolites'. Sammen danner de et unikt fingeraftryk.

Citationsformater